重大事件即時報告 8-K 2026-06-25

報告日期：2026年6月19日

AI 繁中摘要

📄 **申報類型**：8-K（重大事件報告）  
**公司**：Envoy Medical, Inc.（納斯達克代碼：COCH / COCHW）  
**報告日期**：2026年6月19日  

---

### 🧾 主要事件：CEO薪酬調整及股權激勵

Envoy Medical 的薪酬委員會於2026年6月19日批准了行政總裁 Brent Lucas 的薪酬方案更新，具體如下：

- **年薪**：由原水平調整至 **420,000美元**。  
- **現金獎勵**：設定目標獎金 **105,000美元**，將根據2026至2027年期間的特定戰略績效目標達成情況釐定。

### 📈 股權授予

委員會亦批出兩項長期激勵：

1. **股票期權**：共 **1,000,000股**，行使價為 **每股0.634美元**（授予日前一個交易日收市價）。期權分四年歸屬，並附有公司其他標準條款。  
2. **受限股票單位（RSUs）**：共 **1,000,000股**，根據RSU獎勵授予通知及協議（已隨附作附件10.1）發行。歸屬條件為：**美國食品藥品監督管理局（FDA）正式通知批准（包括附條件批准）公司的 Acclaim 人工耳蝸植入物**，且該通知須發生在 **2026年6月19日至2030年6月18日的績效期** 內。

### 🔍 對投資者的潛在影響

- **業績掛鉤獎勵**：現金獎勵及RSU均與公司達成戰略里程碑（特別是FDA批准Acclaim產品）直接掛鉤，顯示管理層與股東利益趨向一致。  
- **稀釋效應**：合共200萬股的新授予（期權及RSU）將對現有股東產生一定攤薄，但若產品成功獲批，長期價值增長可能抵銷影響。  
- **關鍵催化劑**：Acclaim人工耳蝸的FDA審批進度將成為股價核心變數。投資者需密切關注監管更新。

---

**備註**：本摘要僅供參考，不構成任何投資建議。詳細條款請參閱原文8-K申報文件及附件。

展開英文正文

false
 0001840877
 
 
 
 
 
 
 
 0001840877
 
 
 2026-06-19
 2026-06-19
 
 
 
 
 0001840877
 
 COCH:ClassCommonStockParValue0.0001PerShareMember
 
 
 
 2026-06-19
 2026-06-19
 
 
 
 
 0001840877
 
 COCH:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember
 
 
 
 2026-06-19
 2026-06-19
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

FORM
8-K

 

 

 

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date
of Report (Date of earliest event reported): June 19, 2026

 

 

 

ENVOY
MEDICAL, INC.

(Exact
name of registrant as specified in its charter)

 

 

 

 
 Delaware
  
 001-40133
  
 86-1369123

 
 (State
 or other jurisdiction

 of
 incorporation)

  
 (Commission File
 Number)
  
 (IRS
 Employer

 Identification
 No.)

 
 

 
 4875
 White Bear Parkway

 White Bear Lake, MN
  
 55110

 
 (Address
 of principal executive offices)
  
 (Zip
 Code)

 
 

Registrant’s
telephone number, including area code: (877) 900-3277

 

Not
Applicable

(Former
name or former address, if changed since last report)

 

 

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

 

 
 ☐
 Written communications
 pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
 

 
 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
 

 
 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
 

 
 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of each exchange on which registered

 
 Class A Common Stock, par
 value $0.0001 per share
  
 COCH
  
 The Nasdaq Stock Market
 LLC

 
 Redeemable Warrants, each
 whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
  
 COCHW
  
 The Nasdaq Stock Market
 LLC

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging
growth company ☒

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

  

 

 

 Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

 

On
June 19, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of Envoy Medical, Inc.
(the “Company”), approved certain changes to the compensation of the Company’s Chief Executive Officer, Brent
Lucas. Mr. Lucas will receive an updated base salary of $420,000 per year and will be eligible for a cash bonus targeted at $105,000,
which will be determined based on the achievement of certain strategic performance goals intended to be achieved during calendar years
2026 and 2027.

 

The
Committee also approved the issuance to Mr. Lucas of 1,000,000 stock options and 1,000,000 restricted stock units (“RSUs”).
The stock options are exercisable at $0.634 per share (the most recent closing price of the Company’s Class A Common Stock
prior to the grant date), will vest over a period of four years, and will have the Company’s other standard terms. The RSUs were
issued on the form of Restricted Stock Unit Award Grant Notice and Award Agreement, which is filed herewith as Exhibit 10.1 and
incorporated herein by reference, and will vest as of the date of the official notification by the U.S. Food and Drug Administration
(FDA) that it has granted approval (including approval with conditions) for the Company’s Acclaim cochlear implant, provided that
such announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030.

 

Item
9.01 Financial Statements and Exhibits.

 

(d)
Exhibits.

 

 
 Exhibit
No.

  
 Description

 
 10.1
  
 Form of RSU Award Grant Notice and Award Agreement under the Envoy Medical, Inc. Amended & Restated Equity Incentive Plan

 
 104
  
 Cover
 Page Interactive Data File (embedded with the Inline XBRL document).

 
 

 1

  

 

 

SIGNATURES

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

 

 
  

 ENVOY MEDICAL, INC.

 
  
  

 
 June 25, 2026
 By:
 /s/
 Brent T. Lucas

 
  
  
 Brent T. Lucas

 
  
  
 Chief Executive Officer

 
 

 2